Lombard Medical Tech - Appointment of New CFO

Lombard Medical Technologies PLC

("Lombard Medical" or "the Company")

Appointment of New CFO

London, UK, 17 January 2012 - Lombard Medical Technologies PLC (AIM: LMT), the specialist medical technology company focussed on innovative vascular products, is pleased to announce the appointment of Ian Ardill to the Board as Chief Financial Officer, with effect from January 23^rd 2012.

Ian joins Lombard Medical after leaving Biocompatibles International plc, a listed medical technology company, where he was Finance Director for over six years after joining in 2003 as Financial Controller and Company Secretary. Ian played a leading role in transforming the business from a loss making company to a profitable enterprise with sales of £33 million and latterly overseeing the successful sale of the business for £177 million to BTG (LSE: BGC.L - news) plc in 2011.

Before joining Biocompatibles, Ian worked at Novartis Pharmaceuticals UK Limited, in a variety of senior roles that encompassed accounting, systems implementation and treasury (1997-2002). Ian has also held the positions of: Finance Director of Letheby ∓ Christopher Ltd (a subsidiary of Compass Group PLC (Other OTC: CMPGF.PK - news) , 1994-1997), Finance and Planning Manager at NHA International plc (1993-1994) and worked within the corporate finance team at Grant Thornton (1988-1992).

Ian Leslie Ardill (aged 44), qualified as a Chartered Accountant in 1990 and holds an Accounting and Financial Analysis degree from Warwick University.

Lombard Medical Technologies' Chief Executive Officer, Simon Hubbert commented:

"With significant experience in senior finance positions Ian will be a strong addition to the management team and Board, and we are delighted to appoint someone of his calibre. Ian also has considerable business development and international experience in successful medical technology and pharmaceutical companies and will play an important role as we continue to expand Aorfix™ sales in Europe (Chicago Options: ^REURUSD - news) and prepare for its approval in the lucrative US market."

There is no further information to be disclosed in accordance with Schedule Two paragraph (g) of the AIM Rules, save as set out below:

Past directorships in the last 5 years:

Biocompatibles International plc

Biocompatibles UK Limited

Biocompatibles, Inc.

Biopolymerix, Inc.

CellMed AG

- Ends -

About Lombard Medical

Lombard Medical Technologies PLC (AIM: LMT), is a medical device company focused on device solutions for the $1.1 billion dollar per annum abdominal aortic aneurysm (AAA) repair market. AAAs are a balloon-like enlargement of the aorta which, if left untreated, may rupture and cause death. Approximately 4.5 million people are living with AAAs in the developed world and each year 600,000 new cases are diagnosed. The market for endovascular stent grafts for this application is expected to grow to $1.6 billion by 2015. The Company's lead product, Aorfix™, is an endovascular stent graft which has been specifically designed to solve the problems that exist in treating complex tortuous anatomy which is often present in advanced AAA disease. Aorfix™ is currently being commercialised in the EU, and has been submitted to the FDA for approval in the U.S.

The Company is headquartered in Oxfordshire, with operations in Ayrshire and Phoenix, USA.

Further background on the Company can be found at www.lombardmedical.com.

For further information: